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Abstract
Introduction: Although development of anoikis-resistant myofibroblasts during tissue remodeling is known to be
associated with tumor invasion, the mechanism by which myofibroblasts become resistant to anoikis is unknown.
We previously demonstrated laminin-332 upregulation in the fibrosis around invasive ductal carcinoma (IDC).
Because laminin-332 promotes cell survival through binding to integrins, we hypothesized that invasive breast
cancer cells confer an anoikis-resistant phenotype on myofibroblasts by upregulating laminin-332 expression during
tissue remodeling. Here, we demonstrate that invasive breast cancer cells induce laminin-332 upregulation and
integrin b4 neoexpression in myofibroblasts to confer an anoikis-resistant phenotype.
Methods: Three types of fibroblasts were isolated from the tumor burden, the fibrosis, and normal tissue of
patients with early stage IDC (less than 10 mm diameter), designated cancer-associated fibroblasts (CAFs), interface
fibroblasts (InFs), and normal breast fibroblasts (NBFs), respectively. To investigate direct and indirect crosstalk with
tumor cells, fibroblasts were co-cultured with invasive MDA-MB-231 or noninvasive MCF7 cells or in conditioned
medium. Anoikis resistance of fibroblasts was measured by cell viability and caspase-3 activity after incubation on
poly-HEMA coated plates for 72 hours. Involvement of laminin-332/integrin a3b1 or a6b4 signaling in anoikis
resistance was confirmed by treatment with purified laminin-332 or blocking antibodies against laminin-332,
integrin b1, or integrin b4.
Results: MDA-MB-231 cells induced laminin-332 upregulation and integrin b4 neoexpression in fibroblasts, leading
to anoikis resistance. InFs showed a higher endogenous level of laminin-332 than did CAFs and NBFs. After
stimulation with MDA-MB-231-conditioned medium, laminin-332 expression of InFs was dramatically increased and
maintained under anoikis conditions. Laminin-332 upregulation was also observed in CAFs and NBFs, but at a
lower level than in InFs. Laminin-332 induced Akt (Ser473) phosphorylation by binding to integrin a3b1. Integrin
b4 neoexpression induced laminin-332-independent Rac1 activation and promoted anoikis resistance in fibroblasts
approximately twofold more effectively than did laminin-332, regardless of the type of fibroblast. In addition,
integrin b4 expression suppressed fibroblast aggregation in conditions of anoikis.
Conclusion: Invasive breast cancer cells confer an anoikis-resistant phenotype on myofibroblasts during tissue
remodeling by inducing laminin-332 upregulation and integrin b4 neoexpression. Interface fibroblasts appear to be
the primary myofibroblasts that interact with invasive tumor cells during tissue remodeling.
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Introduction
A fundamental component of tumor invasion is stromal
tissue remodeling, which involves proteolytic degrada-
tion of the extracellular matrix (ECM) and results in
anoikis (a form of caspase-dependent apoptosis that is
caused by loss of integrin binding of stromal cells) [1].
As a component of stroma, myofibroblasts are also
exposed to anoikis during tissue remodeling. However,
many studies have reported prolonged survival of myofi-
broblasts during tissue remodeling in patients with
fibrotic diseases [2-5]. Fibrosis is considered an indicator
of tissue remodeling [6] and is commonly formed
around invasive types of tumors [7-9]. Considering that
myofibroblasts are key regulators of tissue remodeling
[10] and a major source of ECM production [11], which
drives tumor progression, the development of anoikis-
resistant myofibroblasts may be an essential event dur-
ing stromal tissue remodeling before tumor invasion.
Abnormal and excessive ECM deposition not only is a
phenotype of fibrosis but also is associated with cell-sur-
vival signaling mediated by integrin receptors during
tumor invasion and tissue remodeling [12]. Therefore,
altered molecular expression in fibrosis may provide a
clue to how myofibroblasts acquire an anoikis-resistant
phenotype during tissue remodeling. Previously, we
observed aberrant laminin-332 upregulation in the fibro-
sis of invasive ductal carcinoma (IDC) compared with
autologous tumor burden and distal normal tissue,
whereas such laminin-332 upregulation was not found
in the noninvasive counterpart, ductal carcinoma in situ
(DCIS) [13]. Contrary to our finding, laminin-332
expression was previously reported to be downregulated
in breast cancer [14]. Laminin-332, a large multidomain
molecule involved in cell adhesion and matrix assembly,
plays an important role in cell migration and survival by
activating many signal mediators through binding to
integrin a3b1 or a6b4 [15-18]. The role of laminin-332
in cell survival or anoikis resistance has been studied
mostly in epithelial tumor cells, although some data
exist on laminin-332-dependent survival of keratinocytes
during wound healing [19,20]. One group demonstrated
that the matricellular protein thrombospondin1 (TSP1)
induces anoikis resistance in mouse embryonic fibro-
blasts in vitro [21]. This work provided convincing evi-
dence that an ECM protein can induce anoikis
resistance in fibroblasts and suggested that laminin-332
may fulfill a similar function. However, because the
fibroblasts used in previous studies were not derived
from tumor stroma, the role of anoikis resistance of
myofibroblasts in the context of tumor invasion remains
undetermined.
In this study, we hypothesized that invasive breast
cancer cells induce laminin-332 upregulation in
myofibroblasts undergoing tissue remodeling, which
leads to anoikis resistance through laminin-332 auto-
crine signaling. To test our hypothesis, we used three
types of fibroblasts isolated from IDC tissue and co-cul-
tured them with breast cancer cells to investigate
tumor-stroma crosstalk. Our results provide evidence
that anoikis-resistant myofibroblasts develop during tis-
sue remodeling of invasive breast cancer as a result of
abnormal upregulation of ECM proteins and/or their
receptors.
Materials and methods
Isolation of primary fibroblasts
Human breast tumors and autologous normal breast tis-
sues were obtained from three IDC patients undergoing
surgery at Severance Hospital of the Yonsei University
Health System, Korea. The protocol for the study was
approved by Severance Hospital Ethics Committee (4-
2008-0380). All participants signed written informed
consent forms detailing tissue use for comprehensive
experiments on breast cancer. Based on the zonal con-
cept proposed in our previous study, primary fibroblasts
were isolated from tissue in the tumor zone (TZ, tumor
burden), interface zone (IF, fibrosis), and normal zone
(distal normal tissue), as described previously [22].
Direct and indirect co-culture
For direct co-culture, primary fibroblasts were cultured
with MCF7 or MDA-MB-231 breast cancer cells (Kor-
ean Cell Line Bank, Seoul, Korea), as described pre-
viously [23]. MDA-MB-231 and MCF7 cells were
selected as representative invasive and noninvasive types
of breast cancer, respectively. Adherent fibroblasts were
stained with 5 μM Cell Tracker Green CMFDA (5-
chloromethylfluorescein diacetate; Invitrogen, Eugene,
OR, USA) by incubation at 37°C for 45 minutes. The
dye solution was then replaced with fresh prewarmed
medium, and the cells were incubated at 37°C for
another 2 hours. After washing them twice with PBS,
unstained cancer cells were plated onto a layer of
CMFDA-stained fibroblasts. The co-cultures were incu-
bated in reduced serum media (RSM) composed of
DMEM/F12, 1% FBS, 100 IU/ml penicillin, and 100 μg/
ml streptomycin for 1 week. CMFDA-stained fibroblasts
and unstained breast cancer cells were sorted with flow
cytometry and used for subsequent experiments. For
indirect co-culture, conditioned medium (CM) was pre-
pared by culturing MCF7 or MDA-MB-231 breast can-
cer cells at 80% confluency in RSM for 1 day. The CM
was filtered through a 0.22-μm filter (Millipore, Billerica,
MA, USA) and diluted 1:1 with fresh RSM before addi-
tion to fibroblast cultures, which were incubated for a
further 3 days.
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Transfection of fibroblasts with integrin b4
For transient transfection with integrin b4, fibroblasts (5
× 105 cells/well) were plated on a six-well plate and
transfected with 3 μg pRK6 b4 plasmid DNA (Addgene
plasmid 16037; Addgene, Cambridge, MA, USA; kindly
donated by Dr. FG Giancotti, Cellular Biochemistry and
Biophysics Program, Memorial Sloan-Kettering Cancer
Center, New York, NY, USA) [24], and 3 μl MATRA
(Promokine, Heidelberg, Germany) in a total volume of
200 μl Opti-MEM on a Universal Magnet Plate (Promo-
kine) for 15 minutes. Controls were transfected with 3
μg pRK5.
Anoikis assays
Fibroblasts (5 × 105 cells/well in 1 ml) were added to
either poly-HEMA- or serum-coated wells and incu-
bated at 37°C in 5% CO2 with RSM, MCF-7 CM, or
MDA-MB-231 CM for 6, 24, 48, or 72 hour. Mainte-
nance of suspended fibroblasts in poly-HEMA-coated
wells (anoikis conditions) was monitored by phase
microscopy. Cell viability was measured by addition of
100 µl CCK-8 (Dojindo Molecular Technologies, Inc.,
Rockville, MD, USA) to each well. After incubation at
37°C for 2 hours, fluorescence was measured with a
plate reader (excitation, 530 nm/emission, 580 nm).
Fibroblasts from three IDC patients were assayed in tri-
plicate in at least three separate experiments. For func-
tion-blocking assays, antibodies against integrin b1, b4,
or laminin-332 (Millipore) were added to InF cells
(which have high expression of laminin-332) with
MDA-MB-231 CM and incubated at 37°C in a humidi-
fied 5% CO2 incubator for 24 hours. CAF cells (which
express low levels of laminin-332) were treated with
purified laminin-332 (Abcam, Cambridge, England) in
RSM for 24 hours.
Caspase-3 activity assay
Caspase-3 activity in fibroblast lysates was measured by
using a caspase-3 activity kit (Becton-Dickinson-Phar-
mingen, San Jose, CA, USA). Fibroblasts (5 × 105 cells)
were plated in poly-HEMA-coated-wells with RSM,
MCF7 CM, or MDA-MB-231 CM and treated with
blocking antibodies or purified laminin-332 for 24
hours. Fibroblast lysates were incubated in a 96-well
plate in HEPES buffer with 5 µl caspase-3 fluorogenic
substrate (Ac-DEVD-AMC) for 1 hour at 37°C in the
dark. Fluorescence was measured with a plate reader
(excitation, 360 nm/emission, 460 nm).
Rac1 pull-down assay
Suspended fibroblasts were harvested by centrifugation
and lysed in 1× lysis buffer. Rac/cdc42 assay reagent (10
µl; 10 µg) was added to 0.5 ml cell lysate, and the reac-
tion mixture was incubated by rocking gently at 4°C for
1 hour. Agarose beads were collected by pulsing for 5
seconds in a microcentrifuge at 14,000 g, and the super-
natant was discarded. The pelleted beads were washed 3
times with 0.5 ml Mg2+ Lysis/Wash Buffer (MLB),
resuspended in 40 µl 5× Laemmli reducing sample buf-
fer, boiled for 5 minutes, separated by polyacrylamide
gel electrophoresis (PAGE), and then detected with
immunoblot.
Immunoblotting
Suspended cells were collected by centrifugation, lysed
in 100 μl Protein Extraction Solution (Intron Biotech,
Seongnan-si, Korea), homogenized with a 30-gauge nee-
dle, incubated for 30minutes at 4°C, and then purified
by centrifugation at 13,000 rpm. After quantifying pro-
teins in the extracts by using the Bradford method, 20
μg protein was electrophoresed on 10% Tris/glycine gels
(Invitrogen, Carlsbad, CA, USA), transferred to polyvi-
nylidine fluoride (PVDF) membranes (Millipore), and
probed with primary antibodies against laminin g2,
integrin a3, integrin a6, integrin b1, integrin b4, Akt,
phospho(Ser473)-Akt, E-cadherin, b-catenin, GAPDH
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), or
Rac1 (Millipore). Primary antibodies were detected with
horseradish peroxidase (HRP)-conjugated secondary
antibodies (Invitrogen), and visualized by using
enhanced chemiluminescence reagents (Santa Cruz
Biotechnology).
Statistics
Statistical significance (indicated by asterisks) was deter-
mined by using the t test and ANOVA. Results were
considered to be significant at P < 0.05. All statistical
analyses were performed by using SPSS version 11.5 for
Windows statistical software (SPSS Inc.).
Results
Invasive breast cancer cells induce upregulation of
laminin-332 expression in stromal fibroblasts
Based on the zonal concept that we previously intro-
duced, stromal fibroblasts were isolated from each zone
of IDC tissue after confirming expression of laminin-g2, a
subunit used to identify laminin-332. Primary fibroblasts
from the tumor zone (TZ), interface zone (IZ), and nor-
mal zone were designated cancer-associated fibroblasts
(CAFs), interface fibroblasts (InFs), and normal breast
fibroblasts (NBFs), respectively. In morphology, InFs
were slightly longer than CAFs and NBFs (Figure 1A).
After culture, InFs expressed a higher level of laminin-g2
than did CAFs and NBFs, as they do in situ, and InFs and
CAFs expressed a higher level of a-SMA did than NBFs
(Figure 1B). To test whether factors secreted by invasive
breast cancer cells can further increase fibroblast lami-
nin-g2 expression, we treated cultured fibroblasts with
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MDA-MB-231 CM. MDA-MB-231 CM dramatically
increased laminin-g2 expression in InFs compared with
CAFs and NBFs. Thus, although MDA-MB-231 CM
enhanced laminin-g2 expression in all fibroblasts, the
degree of increase depended on the intrinsic capacity of
the cells to express laminin-g2. In contrast, MCF7 CM
suppressed laminin-g2 expression (Figure 1C). Because
the IZ is densely fibrotic, a hallmark of the tissue remo-
deling that leads to anoikis of stromal cells, the capacity
of InFs to express laminin-332 under anoikis conditions
was evaluated in the absence or presence of MDA-MB-
231 CM stimulation. In InFs stimulated with MDA-MB-
231 CM, overexpression of laminin-g2 was evident at 24
hours and was maintained for 72 hours (Figure 1D).
Because transforming growth factor (TGF)-b is a major
component of MDA-MB-231 CM, we speculated that it
might be responsible for inducing laminin-332 overex-
pression. To test this, we treated InFs with 100 nM
LY2157299, a TGF-b inhibitor, and MDA-MB-231 CM
for 24 hours and found that laminin-g2 expression was
suppressed in the LY2157299-treated InFs (see Addi-
tional file 1, Figure S1).
Integrin b4 neoexpression in fibroblasts is induced
through direct contact with invasive breast cancer cells
Two integrin receptors for laminin-332, integrins a3b1
and a6b4, are associated with signaling pathways for
cell survival. A high level of integrins a3 and a6 expres-
sion was found in the fibroblasts derived from IDC (see
Additional file 1 Figure S2). Integrin b1 was also highly
expressed in the fibroblasts, whereas integrin b4 was not
expressed (Figure 2A). It is widely known that the reper-
toire or pattern of integrin expression in stromal cells
can be changed through communication with tumor
cells. Because the IZ is adjacent to the TZ within tissue,
CAFs and InFs can directly or indirectly communicate
with tumor cells, and, as a result, the pattern of integrin
expression in myofibroblasts may be altered. To test the
effect of indirect communication with tumor cells, the
fibroblasts were stimulated with MDA-MB-231 CM or
MCF7 CM. Integrin b1 expression was not significantly
affected, but remained high, independent of CM stimu-
lation (see Additional file 1, Figure S3A). Integrin b4
expression was also unchanged and remained undetect-
able (see Additional file 1, Figure S3B). For direct
Figure 1 Laminin-332 expression in stromal fibroblasts is upregulated by invasive breast cancer cells. (A) Isolation of stromal fibroblasts
from invasive ductal carcinoma (IDC). Based on the zonal concept introduced in our previous study, fibroblasts were isolated from early-stage
IDC tissue (less than 10 mm diameter) by enzyme digestion after confirmation of laminin-g2 expression. (B) Expression of laminin-g2 and a-SMA
in fibroblasts of IDC. (C) Stimulation of laminin-g2 expression in fibroblasts by CM from cancer cells. Fibroblasts were incubated with RSM, MCF7
CM, or MDA-MB-231 CM for 24 hours. (D) Duration of laminin-g2 expression in interface fibroblasts (InFs) under anoikis conditions. InFs (5 × 105
cell/well) were seeded onto poly-HEMA coated six-well plates with RSM or MDA-MB-231 CM for 72 hours. Suspended cells were collected at 6,
24, 48, and 72 hours, as indicated.
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communication with tumor cells, fibroblasts were co-
cultured with MDA-MB-231 or MCF7 cells. Integrin b1
expression was not affected by direct contact with can-
cer cells, but was highly sustained (Figure 2B). In con-
trast, de novo expression of integrin b4 was induced by
direct contact with MDA-MB-231, but not MCF7, cells
(Figure 2C). Neoexpression of integrin b4 protein was
also detected in fibroblasts after sorting from the co-
culture.
Anoikis resistance of fibroblasts is conferred by binding
of laminin-332 to integrin a3b1 and by neoexpression of
integrin b4
We found that MDA-MB-231 cells induced laminin-332
upregulation and integrin b4 neoexpression in fibro-
blasts, and that the fibroblasts expressed a high level of
integrin a3, a6, and b1 independent of their interaction
with cancer cells (Figure 2, and see Additional file 1,
Figure S2). Therefore, we hypothesized that the fibro-
blasts in IDC overcome anoikis through laminin-332-
dependent survival pathways that are mediated by integ-
rin a3b1 and/or a6b4. For the anoikis assay, laminin-
332 upregulation in fibroblasts was induced by treat-
ment with MDA-MB-231 CM, and integrin b4
neoexpression was induced by transfection with an
integrin b4 plasmid. Integrin b4 overexpression was
confirmed in all transfected fibroblasts (see Additional
file 1, Figure S4). Anoikis resistance of fibroblasts was
examined by measuring their viability under anoikis
conditions. In the absence of integrin b4 expression, the
viability of InFs (which express high levels of laminin-
332) was increased by MDA-MB-231 CM but decreased
by MCF7 CM, compared with the control incubated
with reduced serum media (RSM) only. In the presence
of integrin b4 expression, the viability of InFs was dra-
matically increased at 6 hours and maintained at a level
approximately twofold higher than that without integrin
b4 through 72 hours. In addition, the viability of these
cells was further enhanced by treatment with MDA-
MB-231 CM (Figure 3A). Similar to that of InFs, the
viability of CAFs (which express low levels of laminin-
332) was increased by MDA-MB-231 CM and integrin
b4 induction, although the viability of CAFs was lower
than that of InFs (Figure 3B). The viability of NBFs
(expressing medium levels of laminin-322) showed a
pattern similar to those of InFs and CAFs (Figure 3C).
The viability of the three types of fibroblasts at 72 hours
is directly compared in Figure 3D. Induction of integrin
Figure 2 Integrin b4 neoexpression is induced in fibroblasts through direct contact with invasive breast cancer cells. (A) Endogenous
expression of integrin b1 and b4 in fibroblasts of IDC. Fibroblasts were prestained with CMFDA and cultured in RSM, MCF7 CM, or MDA-MB-231
CM for 72 hours before staining with PE-conjugated anti-integrin b1 or b4 antibodies. (B) Integrin b1 expression and (C) Integrin b4 expression
in fibroblasts cocultured with MCF7 or MDA-MB-231 cells. Confluent fibroblasts on 100-mm dishes were stained with 5 μM CMFDA. MCF7 or
MDA-MB-231 cells (5 × 105) were added to the stained fibroblasts and cocultured for 1 week. Mixed cells were collected and stained with PE-
conjugated anti-integrin b1 or b4 antibodies. Integrin b1 or b4 expression in cocultured fibroblasts was confirmed by immunoblot analysis after
sorting.
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b4 enhanced the viability of all fibroblast types approxi-
mately twofold compared with fibroblasts lacking integ-
rin b4. In contrast, MDA-MB-231 CM only increased
the viability of InFs, and to a lesser extent than did
integrin b4 induction.
To confirm that fibroblast viability was associated with
binding of laminin-332 to integrins a3b1 and/or a6b4,
InFs and InFs/b4 (expressing integrin b4) were first
stimulated with MDA-MB-231 CM to induce laminin-
332 upregulation and then treated with blocking antibo-
dies against laminin-332, integrin b1, or integrin b4.
The viability of both InF and InFs/b4 was inhibited by
blocking integrin b1 and laminin-332, whereas blocking
integrin b4 had little effect (Figure 3E).
To show that the viability of fibroblasts depends on
laminin-332 expression, CAFs (Ln-332-low) were treated
Figure 3 The anoikis resistance of fibroblasts is mediated by binding of laminin-332 to integrin a3b1 and/or integrin b4
neoexpression. Viability of wild-type and integrin b4-expressing (A) InFs, (B) CAFs, and (C) NBFs in the absence or presence of stimulation from
cancer cells under anoikis conditions. The figures show fibroblast viability in RSM (open square), MCF7 CM (open diamond), and MDA-MB-231
CM (open circle) in the absence of integrin b4 expression, and viability in RSM (black square), MCF7 CM (black diamond), and MDA-MB-231 CM
(black circle) in the presence of integrin b4 expression. (D) Direct comparison of fibroblast viabilities. The viability of wild-type and integrin b4-
expressing fibroblasts was compared at 72 hours. Black bar, CAFs; gray bar, InFs; white bar, NBFs; gray box, integrin b4-expressing fibroblasts. (E)
Inhibition of the interaction between laminin-332 and integrin. InF and InF/b4 cells were treated with isotype (black bar) and blocking antibodies
against integrin b1 (dark gray bar), b4 (light gray bar), and laminin-332 (white bar) for 24 hours under anoikis conditions. (F) Increased viability of
CAFs in response to treatment with laminin-332. CAF and CAF/b4 cells were treated with purified laminin-332 (diluted to 10 μM with RSM) in
poly-HEMA-treated 96-well plates for 24 hours. Black bar, untreated CAFs; white bar, laminin-322-treated CAFs. Results are expressed as mean ±
SD. *P < 0.05; **P < 0.03 versus RSM in poly-HEMA-coated wells. Results are averages of three separate experiments.
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with 10 μM purified laminin-332, resulting in increased
viability. The viability of CAFs/b4 was strongly main-
tained, independent of laminin-332 treatment (Figure
3F).
Laminin-332 upregulation and integrin b4 neoexpression
suppress caspase-3 activity in fibroblasts
Anoikis is a form of caspase-dependent apoptosis that
is caused by loss of integrin binding. Because caspase-3
is a key effector in the extrinsic apoptotic pathway, we
examined caspase-3 activity in fibroblasts in the
absence or presence of cancer cell CM for 72 hours.
Without integrin b4 expression, InFs had lower cas-
pase-3 activity than did CAFs and NBFs, and MDA-
MB-231 CM further reduced caspase-3 activity,
whereas MCF7 CM had no effect. In addition, the
induction of integrin b4 dramatically reduced caspase-
3 activity, which also became much less dependent on
MDA-MB-231 CM stimulation. The lowest measured
caspase-3 activity was in InFs/b4 cells stimulated with
MDA-MB-231 CM (Figure 4A). To confirm whether
the caspase-3 activity of fibroblasts is regulated by the
binding of laminin-332 to integrin a3b1 or a6b4, InFs
and InFs/b4 cells were treated with blocking antibodies
against integrin b1, b4, or laminin-332, and their cas-
pase-3 activity was compared. Inhibition of integrin b1
significantly inhibited caspase-3 activity in InFs and
InFs/b4, whereas inhibition of integrin b4 and laminin-
332 had no effect.
Similar to these results, induction of integrin b4 also
reduced caspase-3 activity (Figure 4B). To show further
that the caspase-3 activity of fibroblasts was decreased
by laminin-332 upregulation, CAFs (Ln-332-low) and
CAFs/b4 were treated with 10 μM purified laminin-
332, and the resulting caspase-3 activities were mea-
sured. Treatment with laminin-332 significantly
decreased caspase-3 activity in both CAFs and CAFs/
b4 (Figure 4C).
Enhancement of anoikis resistance by integrin b4
neoexpression is mediated by Rac1 activation
Akt phosphorylation and Rac1 activation are associated
with integrin-mediated anoikis resistance. In the absence
of stimulation from cancer cells, InFs showed a higher
level of phosphorylation of Akt (Ser473) than did CAFs
and NBFs. Akt phosphorylation was enhanced by MDA-
MB-231 CM and decreased by MCF7 CM (Figure 5A).
GTP-bound Rac1 was downregulated in InFs but upre-
gulated in CAFs and NBFs, and MCF7 CM further
increased GTP-bound Rac1 in InFs (Figure 5A). Induc-
tion of integrin b4 expression dramatically increased
GTP-bound Rac1, independent of stimulation from can-
cer cells, but did not have a significant effect on Akt
phosphorylation (Figure 5B).
Integrin b4 neoexpression suppresses aggregation of
fibroblasts under anoikis conditions
Synoikis, the formation of cell aggregates in nonadher-
ent conditions, has been proposed as a mechanism by
which cells overcome anoikis. Therefore, we investigated
the role of synoikis in the anoikis resistance of fibro-
blasts and whether it is affected by laminin-332 upregu-
lation or integrin b4 neoexpression. In the absence of
integrin b4 expression, the fibroblasts aggregated and
formed big clusters under anoikis conditions; this aggre-
gation was not affected by the upregulation of laminin-
332 by MDA-MB-231 CM (Figure 6A). In contrast,
integrin b4 expression suppressed fibroblast aggregation
independent of laminin-332 (Figure 6B). To confirm
whether fibroblast aggregation is caused by integrin b4
expression, rather than binding of laminin-332 to integ-
rins, we treated fibroblasts with blocking antibodies
Figure 4 Laminin-332 upregulation and integrin b4
neoexpression suppressed caspase-3 activity in fibroblasts. (A)
Caspase-3 activity of fibroblasts under anoikis conditions in the
absence or presence of integrin b4 and/or stimulation with CM
from cancer cells. Black bar, CAF; gray bar, InF; white bar, NBF; gray
box, integrin b4-expressing fibroblasts. (B) Caspase-3 activity
according to inhibition of integrin b1 (dark-gray bar), b4 (light-gray
bar), or laminin-332 (white bar). The black bar shows the isotype
control. (C) Effect of laminim-322 treatment on caspase-3 activity in
CAFs. Black bar, untreated CAFs; white bar, laminin-322-treated CAFs.
Results are expressed as mean ± SD. *P < 0.05; **P < 0.03 versus
RSM in poly-HEMA-coated wells. Results are averages of three
separate experiments.
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against integrin b1 or b4. Neither blocking antibody
affected fibroblast aggregation (Figure 6C). Based on
these findings, we suggest that integrin b4 suppresses
fibroblast aggregation in anoikis conditions. Synoikis is
known to depend on E-cadherin-mediated cell-cell
adhesion; therefore, the suppressive effect of integrin b4
expression on fibroblast aggregation may be caused by a
decrease in E-cadherin expression. However, the fibro-
blasts expressing integrin b4 did not show decreased E-
cadherin expression compared with wild-type controls.
Because b-catenin displays E-cadherin on the cell sur-
face, we postulated that downregulation of b-catenin
may be the cause of defective E-cadherin-mediated cell-
cell interaction. Consistent with this notion, b-catenin
expression was decreased in fibroblasts expressing integ-
rin b4 (Figure 6D).
Discussion
In the present work, we hypothesized that myofibro-
blasts gain an anoikis-resistant phenotype during tissue
remodeling through laminin-332 upregulation and integ-
rin b4 neoexpression induced by interaction with inva-
sive breast cancer cells. To prove our hypothesis, we
isolated three types of fibroblasts, CAFs from the tumor
zone (the epicenter of tumor burden), InFs from the
interface zone (fibrosis), and NBFs from the normal
zone (distal normal tissue) of IDC, and co-cultured
them with tumor cells to investigate the tumor-stroma
interaction. InFs, the myofibroblasts undergoing tissue
remodeling, showed a higher resistance to anoikis than
did CAFs and NBFs as a result of their high endogenous
expression level of laminin-332 and its dramatic upregu-
lation by conditioned medium from invasive MDA-MB-
231 cancer cells. In addition, integrin b4 neoexpression
was induced in fibroblasts by cell-to-cell contact with
MDA-MB-231 cells regardless of the type of fibroblast,
and expression of integrin b4 increased anoikis resis-
tance to a level approximately twofold higher than that
induced by laminin-332 upregulation. From these
results, we conclude that invasive breast cancer cells
confer an anoikis-resistant phenotype on myofibroblasts
during tissue remodeling by inducing laminin-332 upre-
gulation and integrin b4 neoexpression, and that InFs
may be the primary myofibroblasts involved in tissue
remodeling during invasion of breast cancer cells.
This may be the first study to describe how myofibro-
blasts acquire an anoikis-resistant phenotype during tis-
sue remodeling by using a model of invasive breast
cancer. Previously, one group reported that transforming
growth factor b1 (TGF-b1) confers an anoikis-resistant
phenotype on normal primary human fetal lung fibro-
blasts [25], and another group showed that the matricel-
lular protein TSP1 induces anoikis resistance in mouse
embryonic fibroblasts [21]. However, the fibroblasts
used in these studies were not derived from tumor
stroma, and we believed that it was necessary to investi-
gate the development of anoikis-resistant myofibroblasts
in the context of tumor progression. Therefore, in this
study, we used IDC to examine the development of
anoikis-resistant myofibroblasts during tissue
remodeling.
We chose to study IDC for two reasons: the first was
the dense fibrosis around the tumor burden, which is a
phenotype of vigorous tissue remodeling [7-9], and the
second was aberrant upregulation of laminin-332 in the
fibrosis (in contrast, laminin-332 upregulation was not
detected in its counterpart, DCIS) [13]. Because lami-
nin-332 is widely known to promote cell survival, the
anoikis resistance of myofibroblasts is likely mediated by
laminin-332-dependent signaling. To test this assump-
tion, we first investigated laminin-322 expression in
CAFs, InFs, and NBFs and found that the expression
pattern in the fibroblasts was the same as that in situ
(Figure 1A). Based on a-SMA expression and their loca-
tion in the tissue, CAFs and InFs are presumed to be
the myofibroblasts that interact with invasive tumor
cells during tissue remodeling.
Figure 5 Integrin b4 neoexpression induces Rac1 activation.
Akt phosphorylation and Rac1 activation is shown in (A) wild-type
and (B) integrin b4-expressing fibroblasts. Wild-type and integrin
b4-expressing fibroblasts were incubated in RSM, MCF7 CM, or
MDA-MB-231 CM under anoikis conditions for 24 hours. Suspended
fibroblasts were harvested for Rac1 pull-down assays.
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Within the interface zone (IZ) adjacent to the tumor
zone (TZ), invasive breast cancer cells may interact with
InFs via cell-to-cell contact at the border between the
TZ and IZ or with diffusible factors away from the bor-
der and within the IZ. It is therefore possible that the
expression of laminin-332 or its receptors, integrin a3b1
and a6b4, is affected differently according to the type of
interaction. To test this notion, fibroblasts were co-cul-
tured with tumor cells to simulate cell-to-cell contact or
were stimulated with the CM from tumor cells to test
the role of diffusible factors. In our previous study, lami-
nin-332 upregulation in the IZ was shown to be asso-
ciated with tumor invasiveness [13]. Thus, MDA-MB-
231 and MCF7 were used as invasive and noninvasive
breast cancer cell types, respectively. After treatment
with MDA-MB-231 CM, but not MCF7 CM, laminin-
g2, a subunit used to identify laminin-332, was upregu-
lated in InFs, and this upregulation was maintained
under anoikis conditions. Expression of laminin-g2 in
CAFs and NBFs was also promoted by MDA-MB-231
CM, but to a lesser extent than in InFs (Figure 1C). The
degree of laminin-g2 induction by diffusible factors pro-
duced by MDA-MB-231 seemed to depend on the endo-
genous capacity of fibroblasts to express laminin-g2.
According to previous reports, TGF-b is a major soluble
factor produced by MDA-MB-231 [26-28]. Therefore,
we examined whether laminin-g2 upregulation by MDA-
MB-231 CM is induced by TGF-b and found that the
Figure 6 Integrin b4 neoexpression suppresses fibroblast aggregation under anoikis conditions. Formation of fibroblast aggregates under
anoikis conditions in (A) the absence or (B) the presence of integrin b4. Fibroblasts (5 × 105) were plated with RSM, MCF7 CM, or MDA-MB-231
CM on poly-HEMA-coated six-well plates and incubated for 24 hours. The formation of cell aggregates was observed with phase microscopy. (C)
The scattering of integrin b4-expressing fibroblasts under anoikis conditions was not affected by blocking the laminin-332/integrin interaction.
Fibroblasts (2.5 × 104) were plated with RSM, MCF7 CM, or MDA-MB-231 CM on poly-HEMA-coated 96-well plates with blocking antibodies
against integrin b1 or b4 (diluted 1:100 with RSM) or MDA-MB-231 CM for 24 hours. (D) Decreased expression of b-catenin may cause reduced
fibroblast aggregation. Suspended cells were collected, lysed, and subjected to Western blot analysis of b-catenin expression.
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TGF-b inhibitor LY2157299 effectively suppressed lami-
nin-g2 expression (see Additional file 1, Figure S1).
Based on this result, we suggest that expression of lami-
nin-322 is at least partially induced by TGF-b secreted
by invasive breast cancer cells. However, further evalua-
tion is required because we did not test other cytokines
that are highly secreted from invasive breast cancer
cells. In contrast to laminin-332 upregulation by MDA-
MB-231 CM, integrins a3, a6, and b1 were highly
expressed in fibroblasts and not affected by either diffu-
sible factors or direct contact with MDA-MB-231 cells
(Figure 2, and see Additional file 1, Figure S3). Integrin
b4 was not endogenously expressed in fibroblasts, but
its expression was newly induced by direct contact with
MDA-MB-231 cells. Almost no difference was found in
the induction of anoikis resistance by integrin b4 neoex-
pression in the different types of fibroblasts.
When in direct contact with invasive breast cancer
cells, the anoikis resistance of InFs involved both integrin
a3b1 and integrin a6b4 as a result of integrin b4
neoexpression. Although both integrins are known recep-
tors for laminin-332, their signaling pathways, signal
duration, and dependency on laminin-332 are different.
In the case of integrin a3b1, signaling was dependent on
laminin-332 binding and mediated by Akt (Ser473) phos-
phorylation (Figure 5A). In contrast, integrin a6b4-
mediated signaling was independent of laminin-332 and
mediated through Rac1 activation (Figure 5B). Anoikis
resistance induced by integrin a6b4 was approximately
twofold higher than that induced by integrin a3b1 (Fig-
ure 3D). This is supported by a report that Rac1 activa-
tion through integrin a6b4 produces a long-lasting
survival signal [18]. Furthermore, the long cytoplasmic
tail of integrin b4 can be phosphorylated by other factors
such as c-Met, independent of laminin-332 [29]. In addi-
tion to anoikis resistance, integrin b4 neoexpression sup-
pressed fibroblast aggregation under anoikis conditions,
possibly as a result of downregulation of b-catenin (Fig-
ure 6D). Many cells overcome anoikis through synoikis,
the formation of cell clusters via E-cadherin-mediated
Figure 7 Two possible mechanisms by which myofibroblasts acquire anoikis resistance via integrin receptors for laminin-332 during
tissue remodeling. Direct and indirect interactions may occur between invasive tumor cells and myofibroblasts in the interface zone of invasive
ductal carcinoma. Myofibroblasts within the interface zone could be stimulated to express laminin-332 by diffusible factors from invasive breast
cancer cells. Binding of laminin-332 to integrin a3b1 on the myofibroblasts turns on a cell-survival signaling pathway mediated by Akt
phosphorylation. In this case, myofibroblasts may simultaneously use synoikis to overcome anoikis. In addition, in the border between the tumor
zone and the interface zone, invasive breast cancer cells can directly interact with myofibroblasts, leading to integrin b4 neoexpression. Once
integrin b4 is induced, myofibroblasts use both integrin a3b1 and a6b4 as receptors for laminin-332, and become resistant to anoikis via Akt
phosphorylation (laminin-332 dependent) and Rac1 activation (laminin-332 independent). Moreover, integrin b4 neoexpression may inhibit
myofibroblast aggregation through downregulation of b-catenin.
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interaction between cells. The expression of E-cadherin
on the cell surface is known to be regulated by b-catenin
[30]; therefore, decreased expression of b-catenin by
integrin b4 neoexpression may cause defective surface
expression of E-cadherin, which in turn suppresses fibro-
blast aggregation. Considering a recent report that myofi-
broblasts in the primary tumor site metastasize to the
lung along with tumor cells [31], in the context of tumor
metastasis, single cells or a small aggregate of myofibro-
blasts may be more likely to undergo distant migration
with invasive tumor cells than might a large cluster.
In summary, two mechanisms seem to exist by which
myofibroblasts acquire anoikis resistance through lami-
nin-integrin signaling during tissue remodeling as a
result of either direct or indirect interaction between
invasive breast cancer cells and myofibroblasts in the
fibrosis (or interface zone) (Figure 7). For indirect inter-
action, factor(s) secreted from invasive tumor cells sti-
mulate myofibroblasts to overexpress laminin-332.
Laminin-332 binds to integrin a3b1 on myofibroblasts
and turns on an autocrine cell survival signal mediated
by Akt (Ser473) phosphorylation. In addition, myofibro-
blasts that lose their attachment spontaneously use
synoikis to overcome anoikis.
Second, direct contact between invasive breast cancer
cells and myofibroblasts induces integrin b4 neoexpres-
sion in the fibroblasts. Consequently, myofibroblasts
express both integrin a3b1 and integrin a6b4 as recep-
tors for laminin-332. In this case, cell-survival signals
are mediated by Rac1 activation and Akt (Ser473) phos-
phorylation. Akt (Ser473) phosphorylation requires
binding of laminin-332 to integrin a3b1, whereas Rac1
activation by integrin a6b4 is not dependent on lami-
nin-332. Furthermore, integrin b4 neoexpression sup-
presses fibroblast aggregation under anoikis conditions,
possibly through downregulation of b-catenin.
Conclusions
Invasive breast cancer cells confer an anoikis-resistant
phenotype on myofibroblasts during tissue remodeling
by inducing laminin-332 upregulation and integrin b4
neoexpression. Our findings indicate that interface fibro-
blasts may be the primary myofibroblasts involved in tis-
sue remodeling during breast cancer invasion.
Additional material
Additional file 1: Supplementary Figures 1, 2, 3, and 4. Figure S1.
TGF-b in MDA-MB-231 CM causes laminin-332 upregulation in InFs.
Figure S2. Endogenous expression of integrins a3 and a6 in IDC
fibroblasts. Figure S3. Expression of integrins b1 and b4 is not affected by
diffusible factors from breast cancer cells. Figure S4. Exogenous
expression of integrin b4 in IDC fibroblasts by transfection.
Abbreviations
CAF: cancer-associated fibroblast (fibroblasts isolated from the TZ); CMFDA:
(5-chloromethylfluorescein diacetate); DCIS: ductal carcinoma in situ; ECM:
extracellular matrix; IDC: invasive ductal carcinoma; InF: interface fibroblast
(fibroblasts isolated from the IZ); IZ: interface zone (tumor-free fibrotic zone
adjacent to tumor burden); Ln-332: laminin-332; NBF: normal breast
fibroblast (fibroblasts isolated from the NZ); NZ: normal zone (normal tissue
neighboring the IZ); Poly-HEMA: poly(2-hydroxyethyl methacrylate); TZ:
tumor zone (tumor burden of IDC).
Acknowledgements
This study was supported by the Korea Healthcare Technology R&D Project,
Ministry for Health, Welfare and Family Affairs, Republic of Korea (CNH
A101264) and by a faculty research grant of Yonsei University College of
Medicine for 2011(6-2011-0106; CNH).
Author details
1Brain Korea 21 Project for Medical Science, Yonsei University College of
Medicine, 134 Sinchon-dong, Seodaemun-gu, Seoul, 120-752, South Korea.
2Severance Biomedical Science Institute (SBSI), Yonsei University College of
Medicine, 134 Sinchon-dong, Seodaemun-gu, Seoul, 120-752, South Korea.
3Department of Pathology, Yonsei University College of Medicine, 134
Sinchon-dong, Seodaemun-gu, Seoul, 120-752, South Korea. 4Global 5-5-10
System Biology, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul, 120-
749, South Korea.
Authors’ contributions
BGK developed the concept and design of the study, performed the
experiments, analyzed and organized the data, and wrote the manuscript.
MQG carried out the isolation of fibroblasts, maintained them for
subsequent experiments, and helped draft the manuscript. YPC performed
cell sorting after co-culture, and participated in the design of the study. SK
was involved in the anoikis assay. HRP and KSK participated in immunoassay.
NHC participated in the selection of patient breast tissue material, the
conception, design and coordination of the study, and helped draft the
manuscript. All authors read and approved the final manuscript.
Competing interests
We declare no conflicts of interest in all participants.
Received: 1 February 2012 Revised: 10 May 2012
Accepted: 6 June 2012 Published: 6 June 2012
References
1. Johnsen M, Lund LR, Romer J, Almholt K, Dano K: Cancer invasion and
tissue remodeling: common themes in proteolytic matrix degradation.
Curr Opin Cell Biol 1998, 10:667-671.
2. Fattman CL: Apoptosis in pulmonary fibrosis: too much or not enough?
Antioxidants Redox Signal 2008, 10:379-385.
3. Maher TM, Evans IC, Bottoms SE, Mercer PF, Thorley AJ, Nicholson AG,
Laurent GJ, Tetley TD, Chambers RC, McAnulty RJ: Diminished
prostaglandin E2 contributes to the apoptosis paradox in idiopathic
pulmonary fibrosis. Am J Respir Crit Care Med 2010, 182:73-82.
4. Jinta T, Miyazaki Y, Kishi M, Akashi T, Takemura T, Inase N, Yoshizawa Y: The
pathogenesis of chronic hypersensitivity pneumonitis in common with
idiopathic pulmonary fibrosis: expression of apoptotic markers. Am J Clin
Pathol 2010, 134:613-620.
5. Uhal BD: Apoptosis in lung fibrosis and repair. Chest 2002, 122:(6
Suppl):293S-298S.
6. Radisky DC, Przybylo JA: Matrix metalloproteinase-induced fibrosis and
malignancy in breast and lung. Proc Am Thorac Soc 2008, 5:316-322.
7. Kawashiri S, Tanaka A, Noguchi N, Hase T, Nakaya H, Ohara T, Kato K,
Yamamoto E: Significance of stromal desmoplasia and myofibroblast
appearance at the invasive front in squamous cell carcinoma of the oral
cavity. Head Neck 2009, 31:1346-1353.
8. Ronnov-Jessen L, Petersen OW, Bissell MJ: Cellular changes involved in
conversion of normal to malignant breast: importance of the stromal
reaction. Physiol Rev 1996, 76:69-125.
9. Dvorak HF: Tumors: wounds that do not heal: similarities between tumor
stroma generation and wound healing. N Engl J Med 1986, 315:1650-1659.
Kim et al. Breast Cancer Research 2012, 14:R88
http://breast-cancer-research.com/content/14/3/R88
Page 11 of 12
10. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA: Myofibroblasts
and mechano-regulation of connective tissue remodelling. Nat Rev Mol
Cell Biol 2002, 3:349-363.
11. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G:
The myofibroblast: one function, multiple origins. Am J Pathol 2007,
170:1807-1816.
12. Giancotti FG: Integrin signaling: specificity and control of cell survival
and cell cycle progression. Curr Opin Cell Biol 1997, 9:691-700.
13. Kim BG, An HJ, Kang S, Choi YP, Gao MQ, Park H, Cho NH: Laminin-332-
rich tumor microenvironment for tumor invasion in the interface zone
of breast cancer. Am J Pathol 2011, 178:373-381.
14. Martin KJ, Kwan CP, Nagasaki K, Zhang X, O’Hare MJ, Kaelin CM,
Burgeson RE, Pardee AB, Sager R: Down-regulation of laminin-5 in breast
carcinoma cells. Mol Med 1998, 4:602-613.
15. Manohar A, Shome SG, Lamar J, Stirling L, Iyer V, Pumiglia K, DiPersio CM:
Alpha 3 beta 1 integrin promotes keratinocyte cell survival through
activation of a MEK/ERK signaling pathway. J Cell Sci 2004, 117:4043-4054.
16. Sehgal BU, DeBiase PJ, Matzno S, Chew TL, Claiborne JN, Hopkinson SB,
Russell A, Marinkovich MP, Jones JC: Integrin beta4 regulates migratory
behavior of keratinocytes by determining laminin-332 organization. J
Biol Chem 2006, 281:35487-35498.
17. Choma DP, Milano V, Pumiglia KM, DiPersio CM: Integrin alpha3beta1-
dependent activation of FAK/Src regulates Rac1-mediated keratinocyte
polarization on laminin-5. J Invest Dermatol 2007, 127:31-40.
18. Zahir N, Lakins JN, Russell A, Ming W, Chatterjee C, Rozenberg GI,
Marinkovich MP, Weaver VM: Autocrine laminin-5 ligates alpha6beta4
integrin and activates RAC and NFkappaB to mediate anchorage-
independent survival of mammary tumors. J Cell Biol 2003, 163:1397-1407.
19. Fujisaki H, Hattori S: Keratinocyte apoptosis on type I collagen gel caused
by lack of laminin 5/10/11 deposition and Akt signaling. Exp Cell Res
2002, 280:255-269.
20. Nguyen BP, Ryan MC, Gil SG, Carter WG: Deposition of laminin 5 in
epidermal wounds regulates integrin signaling and adhesion. Curr Opin
Cell Biol 2000, 12:554-562.
21. Pallero MA, Elzie CA, Chen J, Mosher DF, Murphy-Ullrich JE:
Thrombospondin 1 binding to calreticulin-LRP1 signals resistance to
anoikis. FASEB J 2008, 22:3968-3979.
22. Gao MQ, Kim BG, Kang S, Choi YP, Park H, Kang KS, Cho NH: Stromal
fibroblasts from the interface zone of human breast carcinomas induce
an epithelial-mesenchymal transition-like state in breast cancer cells in
vitro. J Cell Sci 2010, 123:3507-3514.
23. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR:
Carcinoma-associated fibroblasts direct tumor progression of initiated
human prostatic epithelium. Cancer Res 1999, 59:5002-5011.
24. Dans M, Gagnoux-Palacios L, Blaikie P, Klein S, Mariotti A, Giancotti FG:
Tyrosine phosphorylation of the beta 4 integrin cytoplasmic domain
mediates Shc signaling to extracellular signal-regulated kinase and
antagonizes formation of hemidesmosomes. J Biol Chem 2001,
276:1494-1502.
25. Horowitz JC, Rogers DS, Sharma V, Vittal R, White ES, Cui Z, Thannickal VJ:
Combinatorial activation of FAK and AKT by transforming growth factor-
beta1 confers an anoikis-resistant phenotype to myofibroblasts. Cell
Signal 2007, 19:761-771.
26. Arrick BA, Korc M, Derynck R: Differential regulation of expression of three
transforming growth factor beta species in human breast cancer cell
lines by estradiol. Cancer Res 1990, 50:299-303.
27. Zajchowski D, Band V, Pauzie N, Tager A, Stampfer M, Sager R: Expression
of growth factors and oncogenes in normal and tumor-derived human
mammary epithelial cells. Cancer Res 1988, 48:7041-7047.
28. Dickson RB, Bates SE, McManaway ME, Lippman ME: Characterization of
estrogen responsive transforming activity in human breast cancer cell
lines. Cancer Res 1986, 46:1707-1713.
29. Chan PC, Chen SY, Chen CH, Chen HC: Crosstalk between hepatocyte
growth factor and integrin signaling pathways. J Biomed Sci 2006,
13:215-223.
30. Fukunaga Y, Liu H, Shimizu M, Komiya S, Kawasuji M, Nagafuchi A: Defining
the roles of beta-catenin and plakoglobin in cell-cell adhesion: isolation
of beta-catenin/plakoglobin-deficient F9 cells. Cell Struct Funct 2005,
30:25-34.
31. Duda DG, Duyverman AM, Kohno M, Snuderl M, Steller EJ, Fukumura D,
Jain RK: Malignant cells facilitate lung metastasis by bringing their own
soil. Proc Natl Acad Sci U S A 2010, 107:21677-21682.
doi:10.1186/bcr3203
Cite this article as: Kim et al.: Invasive breast cancer induces laminin-
332 upregulation and integrin b4 neoexpression in myofibroblasts to
confer an anoikis-resistant phenotype during tissue remodeling. Breast
Cancer Research 2012 14:R88.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Kim et al. Breast Cancer Research 2012, 14:R88
http://breast-cancer-research.com/content/14/3/R88
Page 12 of 12
